Decreased blood pressure, pulse pressure and heart rate under treatment with valsartan alone or combined with hydrochlorothiazide: Results of an open trial in 11447 hypertensives;Blutdrucksenkung, blutdruckamplitude und herzfrequenz unter therapie mit valsartan oder valsartan/hydrochlorothiazid: Ergebnisse einer offenen beobachtungsstudie mit 11 447 hypertonikern

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 11, 2003, Pages 541-544

  Weisser, Burkhard ^a   Vetter, H ^a   Mengden, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; SAFETY; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; VALINE;

EID: 0344148452     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37855     Document Type: Article

References (16)

1. Blacher J, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160:1085-1089
2. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide, to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823
3. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675
4. Cushman WC, Materson BJ, Williams DW, Reda DJ for the Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38: 953-957
5. Domanski M, Norman J, Wolz M, Mitchell G, Pfeffer M. Cardiovascular risk assessment using pulse pressure in the first national health and nutrition examination survey (NHANES 1). Hypertension 2001; 38: 793-797
6. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151
7. Labat C, Lacolley P, Lajemi M, de Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension 2001; 38: 439-443
8. Langtry HD. McClellan KJ. Valsartan/hydrochlorothiazide. Drugs 1999; 57: 751-755
9. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-Heft). Circulation 2002; 106: 2454-2458
10. Oparil S, Dyke S, Harris F et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810
11. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3-17
12. Rawlings MD. Postmarketing surveillance of adverse reactions. BMJ 1984; 288: 879-880
13. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872
14. Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice. Results from two postmarketing surveillance studies involving 54928 patients with essential hypertension. Clin Drug Invest 2000; 20: 1-7
15. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042
16. Weisser B, Ripka O. Long-term diuretic therapy. Effects of dose reduction on antihypertensive efficacy and counterregulatory systems J Cardiovasc Pharmacol 1992; 19: 361-366